Teriparatide injection - Asahi Kasei Pharma

Drug Profile

Teriparatide injection - Asahi Kasei Pharma

Alternative Names: hPTH - Asahi Kasei Pharma; MN-10-T; PTH injection - Asahi Kasei Pharma; Teribone; Teriparatide acetate injection

Latest Information Update: 19 Jan 2017

Price : $50

At a glance

  • Originator Asahi Kasei Pharma Corp
  • Developer Asahi Kasei Pharma Corp; Dong-A ST
  • Class Osteoporosis therapies; Peptide hormones; Skin disorder therapies
  • Mechanism of Action Osteogenesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Osteoporosis

Most Recent Events

  • 22 Dec 2016 Asahi Kasei plans a phase III trial for Osteoporosis in Japan (JapicCTI163477)
  • 01 Nov 2016 Asahi Kasei Pharma initiates enrolment in a phase III trial for Osteoporosis in Japan (JapicCTI-163477)
  • 04 Aug 2016 Asahi Kasei plans a phase II trial for Osteoarthritis in Japan (UMIN000022598 )
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top